Key Highlights
• Atara Biotherapeutics notified its chief accounting officer of her termination.
• The board appointed Kevin G. Sarney as interim chief financial officer under a consulting agreement with Charles River CFO, Inc.
• Sarney will provide financial oversight during the change.
Atara Biotherapeutics Inc. (NASDAQ: ATRA) disclosed a key executive transition affecting its finance team. The company confirmed the departure of its chief accounting officer and introduced a seasoned interim chief financial officer to maintain financial oversight during the change.
Departure Announcement
On June 22, 2026, Atara Biotherapeutics informed its chief accounting officer that her employment would conclude on July 17, 2026. The chief accounting officer had served the firm, overseeing regulatory reporting and accounting functions.
Interim CFO Selection
Four days later, the board appointed Kevin G. Sarney as interim chief financial officer. Sarney will act as both the principal financial officer and principal accounting officer while the company searches for a permanent replacement.
Consulting Agreement Structure
Sarney’s services are provided through a consulting agreement with Charles River CFO, Inc. Under the agreement, Atara will pay for Sarney’s work; he will not receive direct compensation from the company. Either party may terminate the arrangement with written notice.
Professional Background
Kevin G. Sarney brings extensive finance and accounting expertise within the life-science sector. He has consulted for Charles River CFO, Inc. Delivering strategic financial guidance to biotech and pharmaceutical firms. Earlier roles included senior finance positions at public and private life-science companies and an auditing stint at a major accounting firm.
He holds multiple degrees and is a licensed CPA.
Governance and Independence
No conflicts of interest were identified; there are no familial ties or related-person transactions linking Sarney to Atara’s leadership team.
Regulatory Compliance
All disclosures comply with regulatory standards, ensuring transparency for shareholders. The filing confirms that the interim appointment adheres to regulatory standards and reflects Atara’s commitment to stable financial governance. Atara Biotherapeutics operates in the biotech sector, where financial management is crucial for development and growth.
The appointment of an experienced interim CFO is a common practice in this sector, allowing companies to maintain continuity during leadership transitions.
This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.






Please wait processing your request...